Bristol-Myers Squibb reports that the U.S. Food and Drug Administration has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy … more

Separately, BMS reports that is has received the Prix Galien USA 2015 Award for Best Biotechnology Product for Opdivo (nivolumab), the Company’s PD-1 immune checkpoint inhibitor … more

Earlier, BMS announced that it has entered into an agreement with Five Prime Therapeutics for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program … more